Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 2, 2013, Pages 325-338

  Lu, Duo ^a,c   Giles, Kurt ^a,b   Li, Zhe ^a,b,d   Rao, Satish ^a,b,e   Dolghih, Elena ^a   Gever, Joel R ^a,b   Geva, Michal ^a,f   Elepano, Manuel L ^a   Oehler, Abby ^b   Bryant, Clifford ^a   Renslo, Adam R ^a   Jacobson, Matthew P ^a   DeArmond, Stephen J ^a,b   Silber, B Michael ^a,g   Prusiner, Stanley B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Endocyte Inc ^*  (United States)

^e Endocyte Inc   (United States)

^f TEVA PHARMACEUTICALS   (Israel)

^g ELMEDTECH LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PYRIDINECARBOXALDEHYDE 2 [4 (5 OXAZOLYL)PHENYL]HYDRAZONE; AMIDE; GREEN FLUORESCENT PROTEIN; HYDRAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPRION ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOLUMINESCENCE; BRAIN TISSUE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MEDIAN EFFECTIVE CONCENTRATION; MOUSE; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TRANSGENIC MOUSE;

AMIDES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HYDRAZONES; INFECTIOUS DISEASE INCUBATION PERIOD; KAPLAN-MEIER ESTIMATE; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PRION DISEASES; PRPSC PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84886032445     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.205799     Document Type: Article

References (49)

1. Aguzzi A, Sigurdson C, and Heikenwaelder M (2008) Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 3:11-40.
2. Berry DB, Lu D, Geva M., Watts JC, Bhardwaj S, Oehler A, Renslo A.R., DeArmond SJ, Prusiner SB, and Giles K (In press) Drug resistance confounding prion therapeutics. Proc Natl Acad Sci.
3. Carlson GA, Ebeling C, Yang S-L, Telling G, Torchia M., Groth D, Westaway D, DeArmond SJ, and Prusiner SB (1994) Prion isolate specified allotypic interactions between the cellular and scrapie prion proteins in congenic and transgenic mice. Proc Natl Acad Sci USA 91:5690-5694.
4. Carlson GA, Goodman PA, Lovett M, Taylor B.A., Marshall ST, Peterson-Torchia M, Westaway D, and Prusiner SB (1988) Genetics and polymorphism of the mouse prion gene complex: control of scrapie incubation time. Mol Cell Biol 8:5528-5540.
5. Chang G, Guida WC, and Still WC (1989) An internal coordinate Monte Carlo method for searching conformational space. J Am Chem Soc 111:4379-4386 DOI: 10.1021/ja00194a035.
6. Clavaguera F, Bolmont T, Crowther R.A., Abramowski D., Frank S, Probst A, Fraser G., Stalder AK, Beibel M, and Staufenbiel M, et al. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909-913.
7. Dixon SL, Smondyrev AM, Knoll E.H., Rao SN, Shaw DE, and Friesner RA (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20:647-671.
8. Frost B, Jacks RL, and Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284:12845-12852.
9. Ghaemmaghami S, Ahn M, Lessard P., Giles K, Legname G, DeArmond S.J., and Prusiner SB (2009) Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 5:e1000673.
10. Ghaemmaghami S, Ullman J, Ahn M., St. Martin S, and Prusiner SB (2010) Chemical induction of misfolded prion protein conformers in cell culture. J Biol Chem 285: 10415-10423.
11. Ghaemmaghami S, Watts JC, Nguyen H-O, Hayashi S, DeArmond S.J., and Prusiner SB (2011) Conformational transformation and selection of synthetic prion strains. J Mol Biol 413:527-542.
12. Giles K, Glidden DV, Beckwith R, Seoanes R., Peretz D, DeArmond SJ, and Prusiner SB (2008) Resistance of bovine spongiform encephalopathy (BSE) prions to inactivation. PLoS Pathog 4:e1000206.
13. Giles K, Glidden DV, Patel S, Korth C., Groth D, Lemus A, DeArmond S.J., and Prusiner SB (2010) Human prion strain selection in transgenic mice. Ann Neurol 68:151-161.
14. Goulding EH, Schenk AK, Juneja P, MacKay A.W., Wade JM, and Tecott LH (2008) A robust automated system elucidates mouse home cage behavioral structure. Proc Natl Acad Sci USA 105:20575-20582.
15. Grad LI, Guest WC, Yanai A, Pokrishevsky E., O'Neill MA, Gibbs E, Semenchenko V., Yousefi M, Wishart DS, and Plotkin SS, et al. (2011) Intermolecular transmission of superoxide dismutase 1 misfolding in living cells. Proc Natl Acad Sci USA 108: 16398-16403.
16. Hohenberg P and Kohn W (1964) Inhomogeneous electron gas. Phys Rev 136: B864-B871 DOI:10.1103/PhysRev.136.B864.
17. Hwu JR, Lin CC, Chuang S.H., King KY, Su TR, and Tsay SC (2004) Aminyl and iminyl radicals from arylhydrazones in the photo-induced DNA cleavage. Bioorg Med Chem 12:2509-2515.
18. Jorgensen WL and Tirado-Rives J (1988) The OPLS potential functions for proteins. Energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110:1657-1666 DOI:10.1021/ja00214a001.
19. Kaminski GA, Friesner RA, Tirado-Rives J, and Jorgensen WL (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 105: 6474-6487 DOI:10.1021/jp003919d.
20. Kawasaki Y, Kawagoe K, Chen C.J., Teruya K., Sakasegawa Y, and Doh-ura K (2007) Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol 81:12889-12898.
21. Keller AF, Gravel M, and Kriz J (2009) Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells. Glia 57:1130-1142.
22. Kohn W and Sham LJ (1965) Self-consistent equations including exchange and correlation effects. Phys Rev 140:A1133-A1138 DOI:10.1103/PhysRev.140.A1133.
23. 80 and flexible docking of 9-deazaguanine inhibitors into PNP. J Comput Chem 20:1671-1684 DOI:10.1002/(SICI)1096-987X(19991130)20:15,1671:: AID-JCC7.3.0.CO;2-Y.
24. Li J, Browning S, Mahal S.P., Oelschlegel AM, and Weissmann C (2010) Darwinian evolution of prions in cell culture. Science 327:869-872.
25. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, and Lee VMY (2012) Intracerebral inoculation of pathological a-synuclein initiates a rapidly progressive neurodegenerative a-synucleinopathy in mice. J Exp Med 209:975-986.
26. Mahal SP, Baker CA, Demczyk C.A., Smith EW, Julius C, and Weissmann C (2007) Prion strain discrimination in cell culture: the cell panel assay. Proc Natl Acad Sci USA 104:20908-20913.
27. Meyer-Luehmann M., Coomaraswamy J, Bolmont T., Kaeser S, Schaefer C, Kilger E., Neuenschwander A, Abramowski D, Frey P, and Jaton AL, et al. (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313:1781-1784.
28. Mougenot A-L, Nicot S., Bencsik A, Morignat E, Verchère J, Lakhdar L., Legastelois S, and Baron T (2012) Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 33:2225-2228.
29. Münch C., O'Brien J, and Bertolotti A (2011) Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci USA 108: 3548-3553.
30. Peretz D, Scott MR, Groth D, Williamson R.A., Burton DR, Cohen FE, and Prusiner SB (2001) Strain-specified relative conformational stability of the scrapie prion protein. Protein Sci 10:854-863.
31. Powell JH and Gannett PM (2002) Mechanisms of carcinogenicity of aryl hydrazines, aryl hydrazides, and arenediazonium ions. J Environ Pathol Toxicol Oncol 21:1-31.
32. Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95:13363-13383.
33. Prusiner SB (2013) Prions, in Fields Virology (Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, and Roizman B, eds) pp 2418-2456, Lippincott Williams & Wilkins, Philadelphia.
34. Prusiner SB (2012) Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336:1511-1513.
35. Richt JA and Hall SM (2008) BSE case associated with prion protein gene mutation. PLoS Pathog 4:e1000156.
36. Safar JG, Scott M, Monaghan J., Deering C, Didorenko S, Vergara J., Ball H, Legname G, Leclerc E, and Solforosi L, et al. (2002) Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol 20:1147-1150.
37. Scott M, Groth D, Foster D., Torchia M, Yang S-L, DeArmond SJ, and Prusiner SB (1993) Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell 73:979-988.
38. Shalev O, Leida MN, Hebbel R.P., Jacob HS, and Eaton JW (1981) Abnormal erythrocyte calcium homeostasis in oxidant-induced hemolytic disease. Blood 58: 1232-1235.
39. Silber BM, Rao S, Fife K.L., Gallardo-Godoy A, Renslo AR, Dalvie D.K., Giles K., Freyman Y, Elepano M, and Gever JR, et al. (2013) Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice. Pharm Res 30: 932-950.
40. Sc levels in dividing and stationary-phase cells. Bioorg Med Chem.
41. Sim VL (2012) Prion disease: chemotherapeutic strategies. Infect Disord Drug Targets 12:144-160.
42. Stöhr J., Watts JC, Mensinger Z.L., Oehler A., Grillo SK, DeArmond SJ, Prusiner SB, and Giles K (2012) Purified and synthetic Alzheimer's amyloid beta (Ab) prions. Proc Natl Acad Sci USA 109:11025-11030.
43. Tamgüney G., Francis KP, Giles K, Lemus A., DeArmond SJ, and Prusiner SB (2009) Measuring prions by bioluminescence imaging. Proc Natl Acad Sci USA 106: 15002-15006.
44. Telling GC, Haga T, Torchia M., Tremblay P, DeArmond SJ, and Prusiner SB (1996) Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. Genes Dev 10:1736-1750.
45. Trevitt CR and Collinge J (2006) A systematic review of prion therapeutics in experimental models. Brain 129:2241-2265.
46. Wagner J, Ryazanov S, Leonov A., Levin J, Shi S, Schmidt F., Prix C, Pan-Montojo F, Bertsch U, and Mitteregger-Kretzschmar G, et al. (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 125: 795-813.
47. Watts JC, Giles K, Grillo S.K., Lemus A., DeArmond SJ, and Prusiner SB (2011) Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci USA 108:2528-2533.
48. Williamson RA, Peretz D, Pinilla C., Ball H, Bastidas RB, Rozenshteyn R, Houghten R.A., Prusiner SB, and Burton DR (1998) Mapping the prion protein using recombinant antibodies. J Virol 72:9413-9418.
49. Zhu L, Ramboz S, Hewitt D., Boring L, Grass DS, and Purchio AF (2004) Non-invasive imaging of GFAP expression after neuronal damage in mice. Neurosci Lett 367:210-212.